ClinicalTrials.gg

Program

Paclitaxel

Also written as “paclitaxel”, “Paclitaxel Injection” and “IV Paclitaxel”.

Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Ovarian Neoplasms · Neoplasms · Stomach Neoplasms, led by 33 companies.

Furthest: phase 4, since May 2, 200284 company-led studies, 5 open or runningNext primary completion: Nov 18, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb160 open or runningphase 3since May 2, 2002May 2, 2002none ahead
Eli Lilly140 open or runningphase 3since Nov 6, 2000Nov 6, 2000none ahead
Daehwa Pharmaceutical51 open or runningphase 3since Apr 12, 2013Apr 12, 2013none ahead
Achieve Life Sciences40 open or runningphase 3since Nov 8, 2005Feb 10, 2004none ahead
Novartis40 open or runningphase 3since Jan 4, 2006Jan 4, 2006none ahead
Takeda40 open or runningphase 2since Mar 17, 2010Mar 17, 2010none ahead
theradex40 open or runningphase 3since Oct 11, 2001Nov 1, 1999none ahead
Boston Scientific30 open or runningphase 3since Jan 13, 2017May 24, 2007none ahead
Biocad20 open or runningphase 3since Dec 27, 2012Dec 27, 2012none ahead
Ionis Pharmaceuticals20 open or runningphase 3since Jun 6, 2001Jun 6, 2001none ahead
Philogen20 open or runningphase 2since May 25, 2010May 25, 2010none ahead
Swedish Orphan Biovitrum20 open or runningphase 3since Feb 5, 2003Feb 5, 2003none ahead
vascular-biogenics-ltd-operating-as-vbl-therapeutics20 open or runningphase 3since Jan 7, 2018Oct 18, 2012none ahead
baker-norton-pharmaceuticals10 open or runningphase 2since Nov 2, 1999Nov 2, 1999none ahead
CASI Pharmaceuticals10 open or runningphase 2since Nov 13, 2002Nov 13, 2002none ahead
cytran10 open or runningphase 2since Jun 6, 2001Jun 6, 2001none ahead
dong-wha-pharmaceutical-co-ltd10 open or runningphase 1since Sep 8, 2017Sep 8, 2017none ahead
esperance-pharmaceuticals-inc10 open or runningphase 2since Dec 2, 2011Dec 2, 2011none ahead
eurocor-gmbh10 open or runningphase 4since Feb 9, 2010Feb 9, 2010none ahead
geron-corporation10 open or runningphase 2since Dec 2, 2010Dec 2, 2010none ahead
Hanmi Pharmaceutical10 open or runningphase 2since Dec 5, 2011Dec 5, 2011none ahead
Innovent Biologics10 open or runningphase 3since Oct 23, 2016Oct 23, 2016none ahead
mabscale-llc11 open or runningphase 3since Dec 8, 2022Dec 8, 2022Dec 2026phase 3 · NCT05654454
matrix-pharmaceutical10 open or runningphase 2since Aug 10, 2001Aug 10, 2001none ahead
mercator-medsystems-inc10 open or runningno phasesince Feb 13, 2014Feb 13, 2014none ahead
NovoCure10 open or runningphase 2since Sep 15, 2014Sep 15, 2014none ahead
oncotech10 open or runningphase 2since Nov 1, 1999Nov 1, 1999none ahead
shanghai-huaota-biopharmaceutical-co-ltd11 open or runningphase 3since Jan 13, 2026Jan 13, 2026Apr 10, 2028phase 3 · NCT07360132
shanghai-miracogen-inc11 open or runningphase 3since Feb 22, 2023Feb 22, 2023none ahead
tolymph-inc11 open or runningphase 2since Nov 13, 2024Nov 13, 2024Nov 18, 2026phase 2 · NCT06693336
UCB10 open or runningphase 2since Sep 6, 2005Sep 6, 2005none ahead
urotronic-inc10 open or runningphase 2since Jan 30, 2018Jan 30, 2018none ahead
Zydus Lifesciences10 open or runningphase 2since Jan 21, 2000Jan 21, 2000none ahead

Also a collaborator on its studies: jazz-pharmaceuticals-ireland-limited, Eisai, parexel, Daiichi Sankyo, baili-bio-chengdu-pharmaceutical-co-ltd, Arcus Biosciences, Ono Pharmaceutical, compass-therapeutics, abl-bio-inc, wuxi-cds-clinical-research-shanghai-co-ltd, Valerio Therapeutics, immatics-biotechnologies-gmbh, Teva Pharmaceutical Industries, Johnson & Johnson and medarex.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 47 studies since Nov 8, 2005.

  1. Jan 13, 2017Phase 3 study in Peripheral Arterial DiseaseBoston Scientific · NCT03064126 · 440 enrolled · United States, Austria, Belgium and more
  2. Sep 8, 2017dong-wha-pharmaceutical-co-ltd's first study: phase 1 study in Advanced Breast CancerNew to dong-wha-pharmaceutical-co-ltddong-wha-pharmaceutical-co-ltd · NCT03282825 · 18 enrolled · Korea, Republic of
  3. Sep 28, 2017Phase 3 study in RecurrenceDaehwa Pharmaceutical · NCT03315364 · 549 enrolled · Bulgaria, China, Hungary and more
  4. Oct 19, 2017Phase 2 study in RecurrenceDaehwa Pharmaceutical · NCT03326102 · 72 enrolled · United States, Czechia
  5. Jan 7, 2018Phase 3 study in Ovarian Neoplasmsvascular-biogenics-ltd-operating-as-vbl-therapeutics · NCT03398655 · 408 enrolled · United States, Israel, Japan and more
  6. Jan 30, 2018urotronic-inc's first study: phase 2 study in Prostatic HyperplasiaNew to urotronic-incurotronic-inc · NCT03423979 · 80 enrolled · Dominican Republic, Panama
  7. Oct 9, 2018Phase 2 study in Stomach NeoplasmsBristol-Myers Squibb · NCT03704077 · United States, Argentina, Australia and more
  8. Nov 23, 2020Phase 1 study in Advanced Solid TumorDaehwa Pharmaceutical · NCT04675528 · 25 enrolled · Hungary
  9. Nov 4, 2022Phase 2 study in Ovarian NeoplasmsBristol-Myers Squibb · NCT05613088 · 106 enrolled · United States, Australia, Belgium and more
  10. Dec 8, 2022mabscale-llc's first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to mabscale-llcmabscale-llc · NCT05654454 · 620 planned · Russian Federation
  11. Feb 22, 2023shanghai-miracogen-inc's first study: phase 3 study in Advanced or Metastatic Urothelium CancerNew to shanghai-miracogen-incshanghai-miracogen-inc · NCT05754853 · 290 planned · China
  12. Nov 13, 2024tolymph-inc's first study: phase 2 study in CarcinomaNew to tolymph-inctolymph-inc · NCT06693336 · 42 planned · United States, Canada
  13. Jan 13, 2026shanghai-huaota-biopharmaceutical-co-ltd's first study: phase 3 study in Squamous Non-small Cell Lung CancerNew to shanghai-huaota-biopharmaceutical-co-ltdshanghai-huaota-biopharmaceutical-co-ltd · NCT07360132 · 480 planned · China
  14. Oct 28, 2026Phase 2 study terminatedStudy stoppedNCT05613088 · “Business objectives have changed.”

Ahead

  1. Nov 18, 2026Primary completion: phase 2 study in Carcinomatolymph-inc · NCT06693336
  2. Dec 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell Lungmabscale-llc · NCT05654454
  3. Apr 10, 2028Primary completion: phase 3 study in Squamous Non-small Cell Lung Cancershanghai-huaota-biopharmaceutical-co-ltd · NCT07360132

TargetBeta

“Tubulin inhibitor”ChEMBL 37, by rule

Other programs on the same 15 targets

ProgramCompanyFurthest phaseStudies
DocetaxelruleSanofiphase 4199
cabazitaxelruleSanofiphase 421
VinblastineruleTakedaphase 44
desoxyepothilone Brulebeijing-biostar-pharmaceuticals-co-ltdphase 319
plinabulinrulebeyondspring-pharmaceuticals-incphase 38

Studies

The newest 60 of 84 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07360132Squamous Non-small Cell Lung Cancer · China3Not yet recruitingshanghai-huaota-biopharmaceutical-co-ltdApr 10, 2028480
NCT06693336Carcinoma · United States, Canada2Recruitingtolymph-incNov 18, 202642
NCT05754853Advanced or Metastatic Urothelium Cancer · China3Recruitingshanghai-miracogen-incOct 2025290
NCT05654454Carcinoma, Non-Small-Cell Lung · Russian Federation3Recruitingmabscale-llcDec 2026620
NCT05613088Ovarian Neoplasms · United States, Australia, Belgium and more2TerminatedBristol-Myers SquibbJun 17, 2024106
NCT04675528Advanced Solid Tumor · Hungary1CompletedDaehwa PharmaceuticalDec 12, 202225
NCT03704077Stomach Neoplasms · United States, Argentina, Australia and more2WithdrawnBristol-Myers SquibbFeb 27, 20220
NCT03423979Prostatic Hyperplasia · Dominican Republic, Panama2Completedurotronic-incJun 4, 201980
NCT03398655Ovarian Neoplasms · United States, Israel, Japan and more3Completedvascular-biogenics-ltd-operating-as-vbl-therapeuticsJul 19, 2022408
NCT03326102Recurrence · United States, Czechia2CompletedDaehwa PharmaceuticalDec 13, 202272
NCT03315364Recurrence · Bulgaria, China, Hungary and more3Active, not recruitingDaehwa PharmaceuticalFeb 19, 2024549
NCT03282825Advanced Breast Cancer · Korea, Republic of1UNKNOWNdong-wha-pharmaceutical-co-ltdFeb 201818
NCT03064126Peripheral Arterial Disease · United States, Austria, Belgium and more3CompletedBoston ScientificNov 18, 2019440
NCT02998528Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more3CompletedBristol-Myers SquibbSep 8, 2021505
NCT02954172NSCLC · China3CompletedInnovent BiologicsOct 19, 2018450
NCT02890511Stomach Neoplasms · Korea, Republic of2CompletedDaehwa PharmaceuticalOct 201228
NCT02725268Endometrial Neoplasms · United States, Australia, Belgium and more2CompletedTakedaJul 2, 2019241
NCT02539225Metastatic Gastric Adenocarcinoma · Japan, Korea, Republic of, Taiwan2CompletedEli LillyOct 25, 2017191
NCT02514551Stomach Neoplasms · United States, Belgium, Canada and more2CompletedEli LillyOct 27, 2017245
NCT02477826Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbOct 25, 20242,747
NCT02412722Non-hematologic Malignancy · United States1CompletedTakedaMay 31, 201861
NCT02244502Ovarian Neoplasms · Belgium, Germany, Spain and more2UNKNOWNNovoCureDec 201631
NCT02066103Malignant Airway Obstruction Secondary to Non-small Cell Lung Cancer · United States–Completedmercator-medsystems-incJun 201620
NCT02054884Carcinoma, Merkel Cell · Austria, Denmark, France and more2TerminatedPhilogenDec 31, 201613
NCT01953536Breast Neoplasms2WithdrawnNovartisNov 20160
NCT01839773Stomach Neoplasms · Korea, Republic of3CompletedDaehwa PharmaceuticalAug 2015238
NCT01764022Breast Neoplasms · Belarus, India, Russian Federation and more3CompletedBiocadMar 2015225
NCT01763645Carcinoma, Non-Small-Cell Lung · Belarus, India, Russian Federation and more3CompletedBiocadNov 2014353
NCT01711970Platinum Resistant Ovarian Cancer · United States2Completedvascular-biogenics-ltd-operating-as-vbl-therapeuticsMay 3, 201738
NCT01497470Neoplasms · United States1CompletedAchieve Life SciencesJul 201336
NCT01491217Stomach Neoplasms · Korea, Republic of2UNKNOWNHanmi PharmaceuticalMar 201253
NCT01485848Ovarian Cancer Recurrent · United States2Completedesperance-pharmaceuticals-incMay 201449
NCT01351350Hematologic Neoplasms · United States1CompletedTakedaSep 15, 201768
NCT01256762Breast Neoplasms · United States, Canada2Completedgeron-corporationOct 2012166
NCT01234038Carcinoma, Non-Small-Cell Lung · United States, Hungary, Poland and more2CompletedIonis PharmaceuticalsOct 2012116
NCT01134250Breast Neoplasms · Italy2CompletedPhilogenApr 7, 201448
NCT01091428Ovarian Neoplasms · United States2CompletedTakedaAug 12, 2014191
NCT01066832Instent Restenosis · Germany, Italy, Netherlands4Completedeurocor-gmbhDec 2010276
NCT01024101Head and Neck Neoplasms2CompletedBristol-Myers SquibbDec 200536
NCT01024062Carcinoma, Non-Small-Cell Lung2CompletedBristol-Myers SquibbMar 200560
NCT01023204Breast Neoplasms2CompletedBristol-Myers SquibbJul 200568
NCT00971945Breast Neoplasms · Japan2CompletedBristol-Myers SquibbMar 31, 20086
NCT00971867Head and Neck Neoplasms · Japan2CompletedBristol-Myers SquibbNov 26, 200811
NCT00971841Esophageal Neoplasms2CompletedBristol-Myers SquibbApr 20121
NCT00855764Head and Neck Neoplasms2CompletedBristol-Myers SquibbOct 200636
NCT00796991Advanced Melanoma · United States1CompletedBristol-Myers SquibbNov 200972
NCT00788931Breast Neoplasms · United States, Australia, Belgium and more1CompletedNovartisAug 201015
NCT00573131Esophageal Neoplasms · United States, Czechia, India and more2TerminatedBoston ScientificNov 2010137
NCT00490711Carcinoma, Ovarian Epithelial · Slovakia2CompletedEli Lilly7
NCT00479765Glioblastoma · United States2TerminatedBoston ScientificOct 20094
NCT00394251Breast Neoplasms · United States2CompletedBristol-Myers SquibbMar 1, 2007197
NCT00344552Esophageal Neoplasms · Japan2CompletedBristol-Myers SquibbMar 200853
NCT00343291Carcinoma, Non-Small-Cell Lung · United States2CompletedEli LillyMay 2010121
NCT00337532Head and Neck Neoplasms · Korea, Republic of3CompletedBristol-Myers SquibbJun 200750
NCT00334802Breast Neoplasms · Japan2CompletedEli LillyFeb 200862
NCT00316199Breast Neoplasms · China2CompletedEli LillyApr 200860
NCT00281658Breast Neoplasms · Brazil, China, Hong Kong and more3CompletedNovartisJun 18, 2010444
NCT00272987Breast Neoplasms · United States, Belgium3TerminatedNovartisJul 31, 200963
NCT00269828Carcinoma, Non-Small-Cell Lung · United States, Argentina, Bulgaria and more3TerminatedSwedish Orphan Biovitrum600
NCT00251095Breast Neoplasms · United States3TerminatedAchieve Life SciencesSep 2007821

How it is read

Names in the registry

  • “Paclitaxel”, 114 entries
  • “paclitaxel”, 46 entries
  • “Paclitaxel Injection”, 3 entries
  • “IV Paclitaxel”, 2 entries
  • “TOCOSOL Paclitaxel”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.